scholarly journals Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease

2012 ◽  
pp. 83 ◽  
Author(s):  
Werner Poewe
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Utility ◽  
Extended Release ◽  
Early Parkinson’S Disease

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease

2010 ◽  
Vol 25 (15) ◽  
pp. 2542-2549 ◽  
Author(s):  
Robert A. Hauser ◽  
Anthony H.V. Schapira ◽  
Olivier Rascol ◽  
Paolo Barone ◽  
Yoshikuni Mizuno ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Double Blind ◽  
Once Daily ◽  
Early Parkinson’S Disease

scholarly journals Pramipexole and its Extended Release Formulation for Parkinson's Disease

2011 ◽  
Vol 3 ◽  
pp. JCNSD.S5210 ◽  
Author(s):  
Paul S. Fishman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Immediate Release ◽  
Motor Fluctuations ◽  
Release Formulation ◽  
Extended Release Formulation ◽  
Release Preparation ◽  
Early Parkinson’S Disease ◽  
Release Form

Pramipexole has been a widely used dopamine agonist for the last decade. Recently an extended release formulation of pramipexole has been introduced as both monotherapy for patients with early Parkinson's disease as well as for patients with more advanced disease, as an adjunct to L-DOPA. Along with the enhanced patient compliance seen with once a day dosing, there are other potential advantages of extended release preparations of dopamine agonists. Patients initiated on pramipexole have a lower incidence of developing motor fluctuations including dyskinesia than those initiated on L-DOPA. Pramipexole requires a prolonged dose titration compared to L-DOPA, and generally does not have the efficacy of L-DOPA. The extended release form of pramipexole shows comparable mean and peak serum levels with once a day dosing as seen with three times a day dosing of the immediate release preparation. The extended release preparation has been studied in randomized multicenter clinical trial against both placebo and the immediate release preparation in the setting of early Parkinson's disease as monotherapy and in more advanced patients with motor fluctuations on L-DOPA. In both settings the extended release preparation was superior to placebo and comparable to the immediate release form in efficacy with a similar side effect profile including nausea, sleepiness, leg edema, dyskinesias, hallucinations and impulse control disorders.

scholarly journals Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease

2014 ◽  
Vol 20 (2) ◽  
pp. 142-148 ◽  
Author(s):  
Rajesh Pahwa ◽  
Kelly E. Lyons ◽  
Robert A. Hauser ◽  
Stanley Fahn ◽  
Joseph Jankovic ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Randomized Trial ◽  
Extended Release ◽  
Early Parkinson’S Disease

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease

2010 ◽  
Vol 25 (14) ◽  
pp. 2326-2332 ◽  
Author(s):  
Olivier Rascol ◽  
Paolo Barone ◽  
Robert A. Hauser ◽  
Yoshikuni Mizuno ◽  
Werner Poewe ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Once Daily ◽  
Early Parkinson’S Disease
Sign in / Sign up

Export Citation Format

Share Document